A Multicenter Study to Describe the Frequency and Emergence of ESR1 Mutations in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving First-Line Endocrine Based Therapy
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- AstraZeneca
- 入组人数
- 3,000
- 主要终点
- Prevalence of ESR1 mutations in circulating tumour DNA
研究概览
简要总结
This is a multicountry, multicenter, observational study in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer receiving first-line endocrine-based therapy with an aromatase inhibitor in combination with a CDK4/6 inhibitor. The study aims to describe the prevalence of ESR1 mutations at baseline and the emergence of ESR1 mutations over time using circulating tumor DNA testing in routine clinical practice.
Patients receiving first-line treatment for at least 6 months and no more than 18 months, without evidence of disease progression at study entry, may undergo baseline ESR1 mutation testing. Patients with a negative baseline result may undergo longitudinal monitoring approximately every 3 months, for up to 18 months or 6 testing timepoints, to assess emergence of ESR1 mutations. The study will also describe mutation subtypes, testing methods used in routine practice, selected clinical characteristics, and treatment patterns across participating countries.
详细描述
This is a multicountry, multicenter, observational study designed to determine the prevalence of ESR1 mutations at baseline and to assess the emergence of ESR1 mutations during longitudinal surveillance in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- aBC) receiving first-line treatment with an aromatase inhibitor (AI) in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Eligible patients are adults with histologically or cytologically confirmed HR+/HER2- advanced breast cancer who have been receiving first-line AI plus CDK4/6 inhibitor therapy for at least 6 months and no more than 18 months, without evidence of disease progression according to investigator assessment, and who are willing and able to provide blood samples for circulating tumor DNA (ctDNA) testing at predefined intervals.
Following informed consent, baseline data will be collected in electronic case report forms and will include sociodemographic characteristics, clinical and tumor history, testing methods, and treatment patterns. A baseline blood sample will be collected for ctDNA-based ESR1 mutation testing using testing methods applied in routine clinical practice, including but not limited to quantitative polymerase chain reaction (qPCR), digital polymerase chain reaction (dPCR), and next-generation sequencing (NGS), according to local availability and site capability. Testing will be performed in validated laboratories in accordance with local standard operating procedures.
Patients who are negative for ESR1 mutation at baseline will undergo longitudinal ctDNA monitoring approximately every 12 weeks (+/-4 weeks), for up to 18 months or 6 testing time points from initial testing, whichever occurs first. Patients who test positive for ESR1 mutation at baseline or during follow-up will discontinue further study surveillance and will continue to receive routine clinical care as determined by the treating physician. The date of first ESR1 mutation detection will be recorded.
The primary objectives are to determine the prevalence of ESR1 mutations at baseline and the emergence rate and time to emergence of ESR1 mutations during the surveillance period among patients who are ESR1 negative at initial testing. Secondary objectives include assessment of ESR1 mutation frequency by duration of first-line therapy and by testing method, distribution of specific ESR1 mutation subtypes, co-mutations with other clinically relevant biomarkers when available, patient clinical and sociodemographic characteristics, testing and treatment patterns, and associations between ESR1 mutation status and relevant patient or treatment factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older at the time of informed consent and willing and able to provide informed consent before any study-related procedures.
- •Histologically- or cytologically-confirmed hormone receptor-positive (ER- and/or progesterone receptor-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer.
- •Receiving first-line therapy with an aromatase inhibitor in combination with a CDK4/6 inhibitor for at least 6 months and no more than 18 months, with no evidence of disease progression at study entry, as assessed by the investigator.
- •Able and willing to provide a blood sample for circulating tumour DNA testing for ESR1 mutation assessment at approximately quarterly intervals.
排除标准
- •Evidence of disease progression during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, based on investigator assessment.
- •Known ESR1 mutation status at study entry.
研究组 & 干预措施
Participants with HR-positive, HER2-negative advanced breast cancer
Adults with HR-positive, HER2-negative advanced breast cancer receiving first-line therapy with an aromatase inhibitor plus a CDK4/6 inhibitor for 6 to 18 months without disease progression at study entry. Participants undergo baseline ESR1 mutation testing using circulating tumour DNA; those with a negative baseline result may undergo follow-up testing approximately every 3 months for up to 18 months.
干预措施: Blood sampling (Other)
结局指标
主要结局
Prevalence of ESR1 mutations in circulating tumour DNA
时间窗: At baseline, approximately 3, 6, 9, 12, 15, and 18 months after initial testing
Number and proportion of patients with at least one ESR1 mutation
Emergence of ESR1 mutations during longitudinal ctDNA surveillance
时间窗: At approximately 3, 6, 9, 12, 15, and 18 months after initial testing
Number and proportion of patients who are detected with ESR1 mutation
Time to first detection of an ESR1 mutation
时间窗: From first-line AI plus CDK4/6 inhibitor initiation to first ESR1 mutation detection
Time in months from initiation of first-line treatment with AI and CDK4/6 inhibitors to first detection of ESR1mutation
次要结局
- Prevalence of ESR1 mutations by duration of ongoing first-line AI plus CDK4/6 inhibitor therapy(At baseline and at approximately 3, 6, 9, 12, 15, and 18 months after initial testing)
- Frequency of ESR1 mutation-positive results by testing method(At baseline and at approximately 3, 6, 9, 12, 15, and 18 months after initial testing)
- Distribution of ESR1 mutation subtypes and allele frequency(At baseline and at approximately 3, 6, 9, 12, 15, and 18 months after initial testing)
- Frequency of additional co-mutations among ESR1 mutation-positive participants(At baseline and approximately every 3 months through study completion, up to approximately 18 months after initial ESR1 testing)
- Baseline and follow-up characteristics of the study population(At baseline and at approximately 3, 6, 9, 12, 15, and 18 months after initial testing)
- Relationship between ESR1 mutation status and selected participant and treatment characteristics(At baseline and at approximately 3, 6, 9, 12, 15, and 18 months after initial testing)
- Treatment patterns for advanced breast cancer(From enrolment through study completion, up to approximately 18 months after initial ESR1 testing)
- Prior treatment patterns for early-stage breast cancer(At baseline)